We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 26, 2017 – Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson (JNJ - Free Report) , Abbott Labs (ABT - Free Report) , Medtronic (MDT - Free Report) and Boston Scientific (BSX - Free Report) .
A survey report by Gallup Analytics last month revealed that U.S. adults cited healthcare, the wider industry of medical devices, as the second major problem faced by the country under the new presidential administration. Given the current lack of clarity, let’s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation. These have been driving the sector’s impressive performance despite severe socio-economic and political instability.
Let’s elaborate some of the major long-term drivers of the MedTech sector.
Emerging Market Openings
It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong. In 2016, this industry grew 5%, a pace last seen before the financial crisis.
And when along with the health policy debacle in the United States we also consider the worsening economic condition in Europe, we can conclude that this encouraging global growth comes mainly from the emerging markets like China, India, Latin America and others.
Going by a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India’s MedTech market, the fifth largest in the world, is currently demonstrating 17% annual growth. If this continues, India may give good competition to Japan and Germany by 2022.
Among other emerging geographical regions, Latin America, even in the face of general economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, the Central and South American nations significantly increased per capita spending on healthcare between 2008 and 2014.
Given the huge potential in these regions, long back, Johnson & Johnson had set up manufacturing and R&D centers in Brazil, China and India. The company’s medical device segment of emerging markets is growing three to four times faster than the developed markets.
Abbott Labscontinues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets were up in double digits, driven by strength in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
At Medtronic, in the last-reported first quarter of fiscal 2017, businesses in China, Latin America, and Southeast Asia showed sustained strength, growing in double digits. Overall, Medtronic remains confident about its long-term outlook on emerging markets. The company is focused on developing new public and private partnerships as well as executing channel optimization strategies.
Boston Scientific’s emerging markets business registered 14% organic growth in second-quarter 2017, reflecting a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). The company is currently looking forward to much better performance ahead in China, banking on the recent approval of SYNERGY in China.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubles the market from 1988 through 2016. Its average gain has been a stellar +25% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
For Immediate Release
Chicago, IL – October 26, 2017 – Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson (JNJ - Free Report) , Abbott Labs (ABT - Free Report) , Medtronic (MDT - Free Report) and Boston Scientific (BSX - Free Report) .
Industry: MedTech, Part 2
Link: https://www.zacks.com/commentary/133749/medtech-growing-on-emerging-markets-ma-stocks-to-buy
A survey report by Gallup Analytics last month revealed that U.S. adults cited healthcare, the wider industry of medical devices, as the second major problem faced by the country under the new presidential administration. Given the current lack of clarity, let’s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation. These have been driving the sector’s impressive performance despite severe socio-economic and political instability.
Let’s elaborate some of the major long-term drivers of the MedTech sector.
Emerging Market Openings
It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong. In 2016, this industry grew 5%, a pace last seen before the financial crisis.
And when along with the health policy debacle in the United States we also consider the worsening economic condition in Europe, we can conclude that this encouraging global growth comes mainly from the emerging markets like China, India, Latin America and others.
Going by a recent BCG report, the share of emerging markets, which is currently less than a quarter of global MedTech revenues, is likely to increase to nearly one-third of revenues by 2022. The MedTech market in China, currently the second largest in the world, is projected to grow about 13% annually from 2015 through 2022. India’s MedTech market, the fifth largest in the world, is currently demonstrating 17% annual growth. If this continues, India may give good competition to Japan and Germany by 2022.
Among other emerging geographical regions, Latin America, even in the face of general economic stagnation, holds enormous potential. Per a January 2017 report by MedTech Intelligence, the Central and South American nations significantly increased per capita spending on healthcare between 2008 and 2014.
Given the huge potential in these regions, long back, Johnson & Johnson had set up manufacturing and R&D centers in Brazil, China and India. The company’s medical device segment of emerging markets is growing three to four times faster than the developed markets.
Abbott Labscontinues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets were up in double digits, driven by strength in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.
At Medtronic, in the last-reported first quarter of fiscal 2017, businesses in China, Latin America, and Southeast Asia showed sustained strength, growing in double digits. Overall, Medtronic remains confident about its long-term outlook on emerging markets. The company is focused on developing new public and private partnerships as well as executing channel optimization strategies.
Boston Scientific’s emerging markets business registered 14% organic growth in second-quarter 2017, reflecting a significant increase from 8% growth in 2013. Business in China was once again remarkable (up 20% year over year). The company is currently looking forward to much better performance ahead in China, banking on the recent approval of SYNERGY in China.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubles the market from 1988 through 2016. Its average gain has been a stellar +25% per year.See these high-potential stocks free >>.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.